The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation
Open accessAbstract
Angiotensin II (Ang II) is a potent vasopressor peptide that interacts with 2 major receptor isoforms - AT1 and AT2. Although blood pressure is increased in AT2 knockout mice, the underlying mechanisms remain undefined because of the low levels of expression of AT2 in the vasculature. Here we overexpressed AT2 in vascular smooth muscle (VSM) cells in transgenic (TG) mice. Aortic AT1 was not affected by overexpression of AT2. Chronic infusion of Ang II into AT2-TG mice completely abolished the AT1-mediated pressor effect, which was blocked by inhibitors of bradykinin type 2 receptor (icatibant) and nitric oxide (NO) synthase (L-NAME). Aortic explants from TG mice showed greatly increased cGMP production and diminished Ang II-induced vascular constriction. Removal of endothelium or treatment with icatibant and L-NAME abolished these AT2-mediated effects. AT2 blocked the amiloride-sensitive Na(+)/H(+) exchanger, promoting intracellular acidosis in VSM cells and activating kininogenases. The resulting enhancement of aortic kinin formation in TG mice was not affected by removal of endothelium. Our results suggest that AT2 in aortic VSM cells stimulates the production of bradykinin, which stimulates the NO/cGMP system in a paracrine manner to promote vasodilation. Selective stimulation of AT2 in the presence of AT1 antagonists is predicted to have a beneficial clinical effect in controlling blood pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pitt, B., Segal, R., Martinez, F. A., Meurers, G., Cowley, A. J., Thomas, I., Deedwania, P. C., Ney, D. E., Snavely, D. B., & Chang, P. I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01187-2 · Cited by 1,665
Stoll, M., Steckelings, U. M., Paul, M., Bottari, S. P., Metzger, R., & Unger, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117710 · Cited by 906
Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor
Ichiki, T., Labosky, P. A., Shiota, C., Okuyama, S., Imagawa, Y., Fogo, A., Niimura, F., Ichikawa, I., Hogan, B. L. M., & lnagami, T. (1995) · Nature · doi:10.1038/377748a0 · Cited by 858
Mukoyama, M., Nakajima, M., Horiuchi, M., Sasamura, H., Pratt, R. E., & Dzau, V. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74498-6 · Cited by 768
Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice
Hein, L., Barsh, G. S., Pratt, R. E., Dzau, V. J., & Kobilka, B. K. (1995) · Nature · doi:10.1038/377744a0 · Cited by 742
Nakajima, M., Hutchinson, H. G., Fujinaga, M., Hayashida, W., Morishita, R., Zhang, L., Horiuchi, M., Pratt, R. E., & Dzau, V. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10663 · Cited by 680
Liu, Y. H., Yang, X. P., Sharov, V. G., Nass, O., Sabbah, H. N., Peterson, E., & Carretero, O. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119360 · Cited by 603
Cardiac Actions of Angiotensin II: Role of an Intracardiac Renin-Angiotensin System
Baker, K. M., Booz, G. W., & Dostal, D. E. (1992) · Annual Review of Physiology · doi:10.1146/annurev.ph.54.030192.001303 · Cited by 517
Siragy, H. M., & Carey, R. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119531 · Cited by 485
Pathophysiological Role of Angiotensin II Type 2 Receptor in Cardiovascular and Renal Diseases
Matsubara, H. (1998) · Circulation Research · doi:10.1161/01.res.83.12.1182 · Cited by 478
Self-citation
Cited by
International Union of Pharmacology. XXIII. The Angiotensin II Receptors
de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., & Unger, T. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01458-3 · Cited by 2,132
Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology
Forrester, S. J., Booz, G. W., Sigmund, C. D., Coffman, T. M., Kawai, T., Rizzo, V., Scalia, R., & Eguchi, S. (2018) · Physiological Reviews · doi:10.1152/physrev.00038.2017 · Cited by 1,095
Kamihata, H., Matsubara, H., Nishiue, T., Fujiyama, S., Tsutsumi, Y., Ozono, R., Masaki, H., Mori, Y., Iba, O., Tateishi, E., et al. (2001) · Circulation · doi:10.1161/hc3501.093817 · Cited by 965
Self-citationHypertension: Renin–Angiotensin–Aldosterone System Alterations
te Riet, L., van Esch, J. H. M., Roks, A. J. M., van den Meiracker, A. H., & Danser, A. H. J. (2015) · Circulation Research · doi:10.1161/circresaha.116.303587 · Cited by 706
Carey, R. M., & Siragy, H. M. (2003) · Endocrine Reviews · doi:10.1210/er.2003-0001 · Cited by 603
Counter-regulatory renin–angiotensin system in cardiovascular disease
Paz Ocaranza, M., Riquelme, J. A., García, L., Jalil, J. E., Chiong, M., Santos, R. A. S., & Lavandero, S. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0244-8 · Cited by 561
Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function
KASCHINA, E., & UNGER, T. (2003) · Blood Pressure · doi:10.1080/08037050310001057 · Cited by 458
Li, X. C., Zhang, J., & Zhuo, J. L. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.06.005 · Cited by 435
The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease
Brewster, U. C., & Perazella, M. A. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.09.034 · Cited by 390
Fujiyama, S., Amano, K., Uehira, K., Yoshida, M., Nishiwaki, Y., Nozawa, Y., Jin, D., Takai, S., Miyazaki, M., Egashira, K., et al. (2003) · Circulation Research · doi:10.1161/01.res.0000099245.08637.ce · Cited by 357
Self-citationTissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological Therapy
Bader, M. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105610 · Cited by 345
Hornig, B., Landmesser, U., Kohler, C., Ahlersmann, D., Spiekermann, S., Christoph, A., Tatge, H., & Drexler, H. (2001) · Circulation · doi:10.1161/01.cir.103.6.799 · Cited by 341
Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice
Heximer, S. P., Knutsen, R. H., Sun, X., Kaltenbronn, K. M., Rhee, M.-H., Peng, N., Oliveira-dos-Santos, A., Penninger, J. M., Muslin, A. J., Steinberg, T. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci15598 · Cited by 334
Karnik, S. S., Unal, H., Kemp, J. R., Tirupula, K. C., Eguchi, S., Vanderheyden, P. M. L., & Thomas, W. G. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010454 · Cited by 302
The renin-angiotensin-aldosterone system, glucose metabolism and diabetes
Giacchetti, G., Sechi, L. A., Rilli, S., & Carey, R. M. (2005) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2005.02.003 · Cited by 267
Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide
Berry, C., Touyz, R., Dominiczak, A. F., Webb, R. C., & Johns, D. G. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.281.6.h2337 · Cited by 259
The AT2 receptor—A matter of love and hate
Steckelings, U. M., Kaschina, E., & Unger, T. (2005) · Peptides · doi:10.1016/j.peptides.2005.03.010 · Cited by 257
Fernandes, T., Hashimoto, N. Y., Magalhães, F. C., Fernandes, F. B., Casarini, D. E., Carmona, A. K., Krieger, J. E., Phillips, M. I., & Oliveira, E. M. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.168252 · Cited by 253
Rueckschloss, U., Quinn, M. T., Holtz, J., & Morawietz, H. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000035392.38687.65 · Cited by 216
Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation
Bekassy, Z., Lopatko Fagerström, I., Bader, M., & Karpman, D. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-021-00634-8 · Cited by 167
The role of kinin receptors in cancer and therapeutic opportunities
da Costa, P. L. N., Sirois, P., Tannock, I. F., & Chammas, R. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.12.009 · Cited by 133
“On the other side, AT2R overexpression in transgenic mice stimulated kallikrein activity, kinin generation and B2R activation [169].”
BackgroundNakagawa, Y., Ikeda, K., Akakabe, Y., Koide, M., Uraoka, M., Yutaka, K.-T., Kurimoto-Nakano, R., Takahashi, T., Matoba, S., Yamada, H., et al. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.206185 · Cited by 124
Self-citationThe Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target
Steckelings, U. M., Widdop, R. E., Sturrock, E. D., Lubbe, L., Hussain, T., Kaschina, E., Unger, T., Hallberg, A., Carey, R. M., & Sumners, C. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000281 · Cited by 97
Loria, A. S., Kang, K.-T., Pollock, D. M., & Pollock, J. S. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.168674 · Cited by 48
Role of the angiotensin II system in regulation of ovulation and blood flow in the rat ovary
Mitsube, K., Mikuni, M., Matousek, M., Zackrisson, U., & Brannstrom, M. (2003) · Reproduction · doi:10.1530/rep.0.1250425 · Cited by 22
Chen, H., Peng, J., Wang, T., Wen, J., Chen, S., Huang, Y., & Zhang, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115370 · Cited by 19
Acute effects of ACE inhibition on coronary endothelial dysfunction
Nickenig, G., Stäblein, A., Wassmann, S., Wyen, C., Müller, C., & Böhm, M. (2000) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2000.067 · Cited by 13
Metadata
- Authors
- Tsutsumi, Y., Matsubara, H., Masaki, H., Kurihara, H., Murasawa, S., Takai, S., Miyazaki, M., Nozawa, Y., Ozono, R., Nakagawa, K., Miwa, T., Kawada, N., Mori, Y., Shibasaki, Y., Tanaka, Y., Fujiyama, S., Koyama, Y., Fujiyama, A., Takahashi, H., & Iwasaka, T.
- Venue
- Journal of Clinical Investigation
- Published
- 1999-10-01
- Volume
- 104
- Issue
- 7
- Pages
- 925-935
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2097489256
- Cited by
- 561
- References
- 38
- FWCI
- 28.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.